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Abstract 
A quarter of patients who develop renal cell 
carcinoma will have metastatic disease at 
presentation. The role of cytoreductive surgery in 
these patients is a topic of debate.   
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The aim of this study was to analyse 
survival outcomes of patients treated in Malta who 
did and did not receive a nephrectomy.  
Data was gathered retrospectively from the 
Malta Cancer Registry and Mortality Data at the 
Department of Health Information, records of 
multidisciplinary team meetings held within the 
urology department at Mater Dei Hospital, hospital 
imaging and patient records. Data gathered 
included: patient demographics, date of diagnosis, 
TNM staging, tumour histology, Fuhrman grade, 
time to treatment and modality of treatment. 
Exclusions included: 
• Localized disease relapsing after surgery
• Non-renal cell histological subtypes
• Presence of metastasis at diagnosis not certain
• Concomitant primary tumours
77 patients diagnosed over 5 years between 
04.03.2005 and 13.2.2009 were included. The age 
at presentation ranged from 30 to 88 years, with a 
median age of 67 years. 11 were incidental findings 
and 47 were symptomatic. The most prevalent 
symptoms were abdominal pain and gross 
haematuria.  
Five-year cancer specific survival in patients 
who received a nephrectomy was significantly 
better at 65%, compared to patients who did not 
undergo surgery (32%) P value <0.05, CI 95%. 
These results where compared favourably with 
SEER data outcomes 
Keywords 
Renal cell cancer, cytoreductive nephrectomy, 
cancer specific survival. 
Introduction 
Renal cell carcinoma (RCC) is one of the ten 
most common malignancy in both men and women. 
The American Cancer Society estimates that 
62,700 new cases of renal cell carcinoma (39,650 in 
Local survival outcomes in metastatic renal cell 
carcinoma 
Gerald Busuttil, Joseph Attard, David Farrugia, John Sciberras, 
Stephen Mattocks, Karl German, Patrick Zammit 
Gerald Busuttil FEBU, FRCSEd* 
Urology unit,  
Department of Surgery,  
Mater Dei Hospital 
Msida, Malta 
geraldbusu@gmail.com 
Joseph Attard MD, MRCSEd 
Department of Surgery  
Mater Dei Hospital 
Msida, Malta 
David Farrugia MD, MRCSEd 
Urology Unit 
Department of Surgery 
Mater Dei Hospital 
Msida, Malta 
John Sciberras MD, FRCSEd (Urol) 
Urology Unit 
Department of Surgery 
Mater Dei Hospital 
Msida. Malta 
Stephen Mattocks FRCS(Urol), FEBU 
Urology Unit 
Department of Surgery 
Mater Dei Hospital 
Msida, Malta 
Karl German MS, FRCS(Urol) 
Urology Unit 
Department of Surgery  
Mater Dei Hospital 
Msida. Malta 
Patrick Zammit FRCS(Ed), FEBU 
Urology Unit  
Department of Surgery  
Mater Dei Hospital  
Msida, Malta 
*Corresponding Author
23Malta Medical School Gazette    Volume 01 Issue 01 2017
gOdRe Original Article 
            
men and 23,050 in women) will be diagnosed in 
2016 in the USA, with 14,240 people (9,240 men 
and 5,000 women) dying from this disease. 1 Local 
data from the European Cancer Observatory for 
2012 cites a Maltese incidence and mortality from 
RCC of 57 and 27 per 100, 000 population (age 
standardised) respectively.2
The incidence of RCC has increased over the 
last decade, and although there has been a definitive 
stage migration to low stage disease, this being 
attributed to increasing use of cross sectional 
imaging and  incidental diagnosis of RCC , up to 
25% of cases are metastatic at diagnosis.3 The 
prognosis in these cases is dismal with the 
American Joint Committee on Cancer quoting only 
an 8% five-year overall survival for stage IV RCC.4
Faced with these poor outcomes and paucity 
of oncological alternative therapies, the urological 
community investigated the benefit of cytoreductive 
nephrectomy in the presence of distant metastases, 
and showed a survival benefit when combined with 
interferon therapy.5-6 More recently, the 
development of targeted therapies has led to the 
substitution of interferon therapy by these drugs in 
view of their superior efficacy and adverse effect 
profile. 7  In the local setting, sunitinib (Sutent®), a 
tyrosine kinase inhibitor, has been the sole agent in 
use for many years, although more recently 
everolimus has also been introduced as second line 
therapy for patients progressing on sunitinib or first 
line therapy for poor prognosis metastatic cases. 
The role of cytoreductive nephrectomy in 
combination with these new agents is still a 
controversial issue.8-9
In this retrospective, non-randomised 
observational study we compared survival 
outcomes in a local population of patients with 
metastatic renal cell carcinoma receiving Sunitinib 
treatment with or without nephrectomy. 
Method 
The aims of this study where to analyse cancer 
specific survival in patients with metastatic RCC in 
Mater Dei Hospital Urology Unit, compare 
outcomes between patients having cytoreductive 
nephrectomy with patients receiving oncological 
management with sunitinib monotherapy, analyse 
survival in patients stratified according to MSKCC 
prognostic groups, and compare these results with 
National Cancer Institute Surveillance, 
Epidemiology and End Results (SEER) program 
database outcomes. 
All patients presenting with metastatic renal 
cell carcinoma to the Urology Unit at Mater Dei 
Hospital between 04.03.2005 and 13.2.2009 were 
retrospectively considered for inclusion. The 
diagnosis was based on radiological investigations.  
Histological confirmation of cancer types was not 
mandatory in patients who did not receive a 
nephrectomy in view of the high diagnostic 
specificity and sensitivity of cross sectional imaging 
in the diagnosis of solid or complex cystic renal 
masses.  
Patients were excluded if their primary disease 
was a non-renal cell kidney cancer, the presence of 
distant metastases was in doubt at time of diagnosis, 
the metastatic progression occurred in the context of 
localised disease at diagnosis that relapsed at a 
distant site following surgery with curative intent or 
the presence of other primary tumours prior to or 
following diagnosis of renal cell cancer. Patients 
were also excluded if they did not receive at least 
one dose of sunitinib adjuvant therapy. 
Data was gathered retrospectively from the 
Malta Cancer Registry and Mortality Data at the 
Department of Health Information, records of 
multidisciplinary team meetings held within the 
Urology department at Mater Dei Hospital, hospital 
imaging and patient records. Mortality data was 
corroborated by death certification data obtained 
from the National Cancer Registry to minimise 
inaccuracy. 
Data gathered included: patient demographics, 
date of diagnosis, TNM staging, tumour histology, 
Fuhrman grade, time to treatment and modality of 
treatment. 
The patients were risk stratified according to 
the revised Memorial Sloan Kettering Cancer 
Center (MSKCC) prognostic risk groups for 
metastatic renal cancer. These represent a revision 
of the original Motzer criteria, 10 updated by Heng 
et al in 2009 to reflect the introduction of targeted 
therapy in the management of metastatic kidney 
cancer.11 These have been externally validated in an 
independent large series.12
The prognostic factors that are included in this 
model include; Karnofsky performance score 
<80%, time to treatment <1 year, anaemia, 
hypercalcaemia, neutrophilia and thrombocytosis. 
Patients were risk stratified into three groups as 
follows; good prognosis if 0 factors, intermediate 
prognosis if 1 – 2 factors, poor prognosis if >2 
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factors as in the original paper by Heng et al. 
Long term cancer specific survival outcome 
was compared between two patient groups, those 
who received cytoreductive nephrectomy and those 
who did not.  Cancer specific survival was also 
investigated in a subgroup analysis per MSKCC 
prognostic group stratification. Survival between 
the two groups was documented via Kaplan Meier 
survival curves, with a p value of <0.05 taken to 
represent significance. 
 
Results  
77 patients satisfied the inclusion criteria. The 
study period selected allowed for the analysis of 
long term survival data in this patient population, 
with the shortest assessment interval (to death or 
ongoing survival) being 3.5 years.  The majority of 
patients enrolled were male, 53, as opposed to 24 
female patients.  The median age at presentation 
was 67 years with a range from 30 years to 88 
years.  
14% of cases were incidental diagnoses, 
whilst 61% of patients presented with symptoms 
related to local or metastatic disease.  In 25% of 
cases the method of presentation was not available.  
The most common symptoms at presentation where 
abdominal or loin pain (21%), gross haematuria 
(19%), lung (13%) or spinal (11%) symptoms. 
(Figure 1). 
The vast majority of cases presented with T3 
or T4 tumours at diagnosis, as per UICC 
International Union Against Cancer, 7th Edition.13 
(Figure 2). 47 were clinically node negative at 
presentation, whilst 29 cases had radiological 
evidence of regional lymph node metastases, lymph 
node status was not documented in one patient.  All 
patients had radiological evidence of distant 
metastases at time of diagnosis, thus being 
classified as TNM stage IV.  
 
 
Figure 1:  Presenting features in symptomatic cases 
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Figure 2: Local Tumour stage at diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Kaplan Meier Curves showing improved cancer survival in nephrectomy group. 
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Figure 4: Kaplan Meier curve for MSKCC good, intermediate and poor prognosis groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histological subtype was known in only 40% 
in view of the fact that most patients did not have 
radical surgery or biopsy of metastatic lesions but 
diagnosis relied on imaging.  In those patients 
where histology subtype was known, clear cell RCC 
was the predominant type in keeping with RCC 
epidemiological patterns (clear cell 27 cases, 
papillary 2 cases, chromophobe 2 cases). 
 25 (32.5%) patients underwent cytoreductive 
open radical nephrectomy during the study period.  
45 patients (58%) had passed away at time of 
censoring (18/8/2015). 
Five-year specific survival in patients who 
received a nephrectomy was significantly better at 
65%, compared to patients who did not undergo 
surgery (32%) P value <0.05, CI 95% as showing in 
Figure 3. 
Subgroup analysis with stratification per 
MSKCC prognostic risk factors was performed. 17 
patients were classified as good prognosis, 49 were 
considered to have an intermediate prognosis and 
10 patients were included into the poor prognosis 
group.  Insufficient data prevented accurate 
stratification in one patient who was excluded from 
subgroup analysis.   
Five-year survival data showed a significant 
0 1 2 3 4 5
Time in Years
Disease Speciﬁc Survival by MSKCC Group
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difference between the good prognosis and 
intermediate prognosis groups with a trend towards 
a poorer outcome in the intermediate group.  The 
poor prognosis group had better long term outcome 
than the intermediate group, however this is likely 
to represent an outlying and unrepresentative result 
in view of the small number of patients in this 
group. These results are showed graphically in 
Figure 4.   
These results where compared favourably 
with SEER data outcomes,15-16 as shown in Tables 1 
and 2. 
 
Discussion 
In modern day urology, almost one third of 
clear cell renal cell cancers (the predominant 
histological subtype of renal cell carcinoma) present 
with locally advanced or metastatic disease.17  
Given the relatively high incidence of renal cell 
cancer, the urological and oncological community is 
faced with the difficult management of a significant 
number of patients whose disease has a poor long 
term outcome despite aggressive multimodality 
management with surgery and an ever expanding 
armamentarium of targeted therapies.  
This aggressive approach is still a topic of 
debate, as only retrospective non-comparative data 
exists for cytoreductive nephrectomy in 
combination with modern targeted therapies.  The 
pioneering work which explored the role of radical 
surgery in the presence of metastatic disease was 
performed in the era of immunotherapy prior to the 
introduction of targeted biological agents.  A meta-
analysis of these studies, published in the Lancet 
Oncology in 2014, did show an increased long term 
survival in patients treated with surgery and 
immunotherapy compared to patients who received 
immunotherapy alone.18 
 
 
 
Table 1: Cancer specific survival for local patient cohort compared to SEER database data one, two and three 
years. 
 
  Malta (2005-2009) SEER Database (2006-2009)  
  Nephrectomy No Nephrectomy Nephrectomy No Nephrectomy 
1 year 75.2% 51.2% 70.6% 45.1% 
2 years 71% 34.3% 52.2% 27.9% 
3 years 65.3% 26.8% 41.7% 21.7% 
 
Table 2: Cancer specific survival statistics at 5 years, local and US data. 
MSKCC Prognosis  Malta (2005-2009) SEER Database (2006-2009) 
Good  57% 36.2% 
Intermediate 32% 25.1% 
Poor 54% 9.1% 
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Table 3: Published literature investigating role of cytoreductive nephrectomy in combination with targeted 
therapies in the setting of metastatic renal cell cancer. 
  
Study (period studied) Patients, n; 
CN, no CN 
Median OS 
with CN, 
months 
Median OS 
without CN, 
months 
Statistically significant 
patient dispositions in 
favour of CN (p ≤ 0.001 
to p < 0.05) 
Retrospective, multi-
institutional (2004–
2008); 
Choueiri et al., 2011 20 
314; 201, 
113 
19.8 9.4 • Younger age 
• Better KPS 
• One metastatic site 
• Less calcium 
Retrospective, SEER 
(1993–2010); Conti et 
al., 2014 21 
20 104; 
6915, 13 
189 
19 4 • Younger age 
• Male 
• White 
Retrospective, IMDC 
(2005–2013); Heng et 
al., 2014 9 
1658; 982, 
676 
20.6 9.6 • Better IMDC risk 
• Less non–clear cell RCC 
• Fewer bone metastases 
• Fewer liver metastases 
Retrospective, multi-
institutional (2006–
2011); Bamias et al., 
2014 22 
186; 109, 
18 
23.9 9.0 • Younger age 
• Better PS 
• Less neutrophilia 
• Lower LDH 
Retrospective, SEER 
(2005–2009); Abern et 
al., 2014 23 
2382; 1521, 
861 
20 6 • Younger age 
• Male 
• White 
Retrospective, SEER 
non-clear cell RCC only 
(2000–2009); Aizer et 
al., 2014 24 
591; 377, 
214 
14 6 • Younger age 
• Male 
• White 
Retrospective, multi-
institutional (1999–
2009); Mathieu et al., 
2015 25 
351; 298, 
53 
38.1 16.4 • Better MSKCC risk 
• Better ECOG score 
Retrospective 
population-based 
registry, propensity 
score matching (2008–
2010); De Groot et al, 
in press 26 
227; 74, 
151 
17.9 8.8 • T stage <T3/T4 
• One metastatic site 
• Fewer bone metastases 
Retrospective, National 
Cancer Data Base, 
treated with targeted 
therapy (2006–2013); 
Hanna et al, in press 27 
15 390; 
5374, 10 
016 
17.1 7.7 • Younger age 
• Privately insured 
• Academic centre 
• Lower T stage 
• cN0 
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Recently this treatment paradigm was adopted 
by urologists and oncologists and applied to 
metastatic patients who are treated with targeted 
therapies which have replaced immunotherapy in 
modern practice.  The evidence base for this 
approach is not extensive, with no randomised 
controlled trials to support such an approach to date.  
Whilst awaiting the results of two randomised trials 
that are designed to end to this debate, CARMENA 
(ClinicalTrials.gov identifier NCT00930033) and 
SURTIME (ClinicalTrials.gov identifier 
NCT01099423), the European Association of 
Urology recommends surgery in highly selected 
patients with good performance status, large 
primary tumours and low metastatic volume. 17,19 
This approach to metastatic renal cell cancer 
introduces a heavy selection bias with retrospective 
studies, with fitter patients with less aggressive 
disease receiving surgery, whilst those who have a 
poorer performance status or heavy metastatic load 
receiving oncological treatment as monotherapy.  
This inherent flaw cannot obviate the fact that all 
the retrospective studies published to date have 
shown an overall survival advantage with surgery in 
addition to biological agents. (Table 3).  
This trend is also evident in our cohort of 
local patients in which patients who received a 
nephrectomy had a better long term cancer specific 
survival than those patients who did not.  This is the 
most important take home message obtained from 
this retrospective review.   
Subgroup analysis with patient stratified 
according to MSKCC prognostic groups showed 
some unexpected results with the poor prognosis 
group of patients doing better than the intermediate 
risk group.  This can probably be attributed to the 
small number of patients in this group which has 
resulted in a surprising good outcome.   
Compared to SEER data the outcomes in our 
local cohort of patients compare favourably or 
significantly better, in all three risk groups but 
especially in the subgroup who underwent 
nephrectomy.  Again, the vastly superior outcome 
in the poor prognosis group should not be taken as a 
true reflection of clinical outcomes in this very 
small group of patients as already discussed. 
The primary tumour accounted for >90% of 
tumour burden in 55 patients (71.4%), this is an 
important point as it is likely that a cytoreductive 
nephrectomy would benefit patients who have most 
of their tumour mass limited to the kidney. 50 
patients (65%) presented with metastases above the 
diaphragm, this is also relevant as some authorities 
would not offer debulking nephrectomy in patients 
with disease above the diaphragm as this is thought 
to be a very poor prognostic factor with limited 
benefit being obtained with a surgical approach.14 
Being the only urology unit in the country, 
follow up is mostly complete with no patients lost 
to follow up because of migration.  Patients were 
followed up for an adequate period of > 5 years as 
is mandatory in oncology studies where survival is 
the outcome.   
Limitations include those inherent to a 
retrospective audit, including incomplete data, 
reliance on potentially inaccurate medical notes and 
bias. Data on overall survival is not presented, and 
this could reflect real life outcomes in a more 
meaningful way than cancer specific survival. 
 
Conclusions 
Cytoreductive nephrectomy in the presence of 
metastatic renal cell cancer does seem to offer a 
survival advantage as demonstrated in this study 
and other retrospective non-randomised trials.  The 
results from two ongoing large multi-centre 
randomised controlled studies which are addressing 
this issue are eagerly awaited. 
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